Abstract
MHC class II deficiency is a combined immunodeficiency caused by defects in the four regulatory factors, CIITA, RFXANK, RFX5 and RFXAP, that control MHC II expression at the transcriptional level. The RFXANK gene encodes one subunit of the heterotrimeric RFX complex that is involved in the assembly of several transcription factors on MHC II promoters. Seven different RFXANK mutations have previously been reported in 26 unrelated patients. The most frequent mutation, a 26-bp deletion (752delG-25), has been identified in 21 patients. The other mutations are all nonsense or splice-site mutations, leading to proteins lacking all or part of the RFXANK ankyrin repeat region. We report two novel missense mutations, D121V and R212X, resulting in loss of function of the gene. We investigated the in vivo effects of these mutations and of three other point mutations on the expression of the RFXANK RNA and protein. The number of RFXANK transcripts was severely reduced in all patients except one. The RFXANK protein was barely detected in two cases. In addition, guided by a structural model of RFXANK, we investigated experimental mutants of the C-terminal tyrosine 224. Substitution Y224A, but not Y224F, led to the loss of function of RFXANK. Two null mutants, D121V and Y224A, were tested in protein interaction and DNA binding assays. The D121V mutant was unable to form the RFX complex, indicating that D121 is required for RFXAP binding. The Y224A mutant formed an RFX complex that bound normally to the MHC II promoter, but did not lead to MHC class II expression, whereas Y224F RFXANK retained the wild-type function. This indicates that an aromatic ring, but not the phenyl chain of tyrosine, is necessary at position 224 for normal RFXANK function. Studies on the Y224A mutant suggest that, in addition to the RFX subunits and CIITA, another protein is essential for MHC class II expression. This protein appears to interact with the fourth ankyrin repeat of RFXANK.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W and Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389–3402
Batchelor AH, Piper DE, de la Brousse FC, Mc Knight SL, Wolberger C (1998) The structure of GABP alpha/beta: an ETS domain-ankyrin repeat heterodimer bound to DNA. Science 279:1037–1041
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IP, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28:235–242
Brotherton DH, Dhanaraj V, Wick S, Brizuela L, Domaille PJ, Volyyanik E, Xu X, Parisini E, Smith BO, Archer SJ, Serrano M, Brenner SL, Blundell TL, Lane ED (1998) Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19NK4d. Nature 395:244–25021
Cresswell P (1994) Assembly, transport and function of MHC class II molecules. Annu Rev Immunol 12:259–293
DeSandro AM, Nagarajan UM, Boss JM (2000) Associations and interactions between bare lymphocyte syndrome factors. Mol Cell Biol 20:6587–6599
Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B, Reith W (1997) RFXAP, a novel subunit of the RFX DNA binding complex, is mutated in MHC class II deficiency. EMBO J 16:1045–1055
Griscelli C, Fischer A, Grospierre B, Durandy A, Bremard C, Charron, Dvilmer E, Virelizer JL (1984) Clinical and immunological aspects of combined immunodeficiency with defective expression of HLA antigens. Excerpta Medica, Amsterdam
Griscelli C, Lisowska-Grospierre B, Mach B (1993) Combined immunodeficiency with defective expression in MHC class II genes. In: Rosen FS, Seligman M (eds) Immunodeficiencies. Harwood Academic, Chur, Switzerland, pp 141–154
Hasegawa SL, Boss JM (1991) Two B cell factors bind the HLA-DRA X box region and recognize different subsets of HLA class II promoters. Nucleic Acids Res 19:6269–6276
Klein C, Lisowska Grospierre B, LeDeist F, Fischer A, Griscelli C (1993) Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr 123:921–928
Lisowska-Grospierre B, Fondaneche MC, Rols MP, Griscelli C, Fischer A (1994) Two complementation groups account for most cases of inherited MHC class II deficiency. Hum Mol Genet 3:953–958
Louis-Plence P, Moreno CS, Boss JM (1997) Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes. J Immunol 159:3899–3909
Mach B, Steimle V, Martinez-Soria E, Reith W (1996) Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 14:301–331
Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, Sanchez JC, Hochstrasser DF, Mach B, Reith W (1998) A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 20: 273–277
Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A, Boss JM (1999) RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 10: 153–162
Nagarajan UM, Peijnenburg A, Gobin SJ, Boss JM, van den Elsen PJ. (2000) Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells. J Immunol 164:3666–3674
Nakrep N, Jabrane-Ferrat N, Peterlin MB (2000) Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex. Mol Cell Biol 20:4455–4461
Nekrep N, Geyer M, Jabranne-Ferrat N, Peterlin MB (2001) Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome. Mol Cell Biol 21:5566–76
Peretti M, Villard J, Barras E, Zufferey M, Reith W (2001) Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP. Mol Cell Biol 21:5699–709
Steimle V, Otten LA, Zufferey M, Mach B (1993) Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135–146
Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, Reith W (1995) A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 9:1021–1032
Wiszniewski W, Fondaneche MC, Lambert N, Masternak K, Picard C, Notarangelo L, Schwartz K, Bal J, Reith W, Alcaide C, de Saint B, Fischer A, Lisowska-Grospierre B (2000) Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B. Immunogenetics 51:261–267
Acknowledgements
We wish to thank Fabienne Mazerolles for performing the phosphorylation studies and for expert advice. We thank Viktor Steimle and Walter Reith for the critical reading of the manuscript. This work was supported in part by the Progrès Programme (INSERM) and KBN grant No. 4 PO5E 11819. W.W. is a PhD student at the Postgraduate School of Molecular Medicine in Warsaw Medical University and the recipient of a Young Scientist Award from the Foundation for Polish Science.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wiszniewski, W., Fondaneche, MC., Louise-Plence, P. et al. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. Immunogenetics 54, 747–755 (2003). https://doi.org/10.1007/s00251-002-0521-1
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00251-002-0521-1